{"entity":{"id":"nct05516914","kind":"trial","name":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors","aka":[],"tldr":"A phase 1/2 trial of Alcestobart run by Nanjing Leads Biolabs Co.,Ltd, completed.","summary":"A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors is a phase 1/2 interventional study registered as NCT05516914 by Nanjing Leads Biolabs Co.,Ltd, with 98 participants enrolled, started 2022-09-01. Conditions recorded: Malignant Tumors. Interventions recorded: LBL-007 Injection, Tislelizumab Injection, Cisplatin Injection, Gemcitabine Hydrochloride for Injection and Docetaxel injection.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT05516914","url":"https://clinicaltrials.gov/study/NCT05516914"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["alcestobart"],"companies":["nanjing-leads-biolabs"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05516914","phase":"1/2","setting":"A Multicenter Phase Ib/II Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of LBL-007 in Combination With Tislelizumab in the Treatment of Malignancies","sponsor":"Nanjing Leads Biolabs Co.,Ltd","enrolled":98,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct05516914/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"alcestobart","kind":"drug","name":"Alcestobart","route":"/drugs/alcestobart/"}],"company":[{"id":"nanjing-leads-biolabs","kind":"company","name":"Nanjing Leads Biolabs","route":"/companies/nanjing-leads-biolabs/"}]}}